Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label, Interventional Study to Evaluate Subject Satisfaction of AbobutulinumtoxinA Treatments in Moderate to Severe Glabellar Lines

Trial Profile

A Multicenter, Open-Label, Interventional Study to Evaluate Subject Satisfaction of AbobutulinumtoxinA Treatments in Moderate to Severe Glabellar Lines

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary) ; Botulinum-Toxin-A (Primary)
  • Indications Glabellar lines
  • Focus Therapeutic Use
  • Acronyms DREAM
  • Sponsors Galderma; Q-Med
  • Most Recent Events

    • 31 May 2022 According to a Galderma media release, Pooled data from NCT03736928, Phase 2; NCT03960957, Phase 3; NCT03687736, Phase 4 will be presented at the upcoming International Master Course on Aging Science (IMCAS) World Congress 2022 in Paris from June 3-5, 2022.
    • 25 Apr 2021 Results of post-hoc analysis, evaluating subject satisfaction following on-label injections of 50U of AbobotulinumtoxinA in the glabellar lines at baseline and re-treatment at 6 months, presented at the American Academy of Dermatology Virtual Meeting Experience 2021
    • 09 Oct 2020 According to a Galderma media release, results from this study will be presented at the virtual American Society for Dermatologic Surgery (ASDS) 2020 Annual Meeting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top